The global bioresorbable coronary stents market size was valued at USD 140.25 million in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 15.3% from 2023 to 2030. The availability of post-approval, real-world evidence data for Magmaris, Magnitude, and 2nd generation Absorb is expected to be the turning point for the current lagging pace of this market. The placement of these bioresorbable devices enables individuals to live with a normal functioning artery as well as the option to undergo angioplasty in their later years. While still in development, the pediatric patient cohort with genetic coronary conditions is a viable target for these fully dissolvable stents that restore normal vasomotor function and vessel growth.
The COVID-19 pandemic substantially impacted the global market for bioresorbable coronary stents. The healthcare sector faced various challenges during this period. A major pandemic effect was the cancellation or postponement of non-urgent and elective medical procedures, which included coronary stent implantations. The main focus of healthcare facilities shifted towards the treatment of COVID-19 patients as well as conservation of medical resources, causing a reduction in the number of procedures being performed.
The pandemic negatively impacted supply chains globally, leading to difficulties in the production and distribution of medical devices, which included bioresorbable coronary stents. Restrictions on international trade, lockdown measures, and the increased demand for medical supplies resulted in supply shortages, affecting stent availability. Additionally, the fear of contracting the virus and movement restrictions led to fewer patient visits to hospitals and clinics for routine check-ups and consultations. Thus, there were less opportunities for stent implantations, impacting the demand for bioresorbable coronary stents.
A key driver for this market is the gaining count of elective Percutaneous Coronary Intervention (PCI) procedures. This number is on the rise, particularly in the Asia Pacific. Cardiovascular diseases are a major cause for the global stroke occurrence and coronary artery disease rates. Risk factors associated with unhealthy lifestyles that are highly prevalent in urbanized regions underlie the stroke incidence rate, thus giving rise to a strong demand for interventional coronary procedures in young adults. Moreover, the absence of appropriate use criteria guidelines for checking procedure volumes, as well as enactment of the price-capping policy by the National Pharmaceutical Pricing Authority in India has increased the penetration and affordability of these devices.
The MeRes100 brand segment dominated the market and accounted for the largest revenue share of 24.8% in 2022. However, its withdrawal has sparked concerns regarding the safety and efficacy of these fully dissolvable devices, prompting a greater demand for reliable post-approval data from national regulatory bodies. With more promising patient registry data, other lesser-known stents, such as DESolve are emerging rapidly.
The others segment is expected to advance at the fastest CAGR of 16.9% over the forecast period from 2023 to 2030. Anticipated entrants, currently in the pipeline or recently launched, have distinguishing attributes that are expected to offer revival opportunities for the bioresorbable coronary stents market. Amaranth has developed three notable devices, Fortitude, Aptitude, and the last with the thinnest strut, Magnitude, which is expected to prove favorable in clinical follow-up studies.
The first of its kind metallic bioresorbable device, Magmaris, with an underlying metallic body, exerts better radial force than its predecessors in this market. Despite its recent setback, Abbott is focusing on developing another bioresorbable coronary stent (Absorb 2nd G) with alterations to the previous design.
North America led the global industry with the highest revenue share of 37.4% in the market in 2022. The region has an advanced healthcare infrastructure, which includes hospitals, clinics, as well as specialized cardiac centers. These facilities house state-of-the-art equipment along with skilled healthcare professionals that are experienced in performing coronary procedures. Additionally, the United States has a robust healthcare system that encourages technological advancements and innovations. It is home to several notable medical device companies that invest substantially in R&D, driving the development of bioresorbable coronary stents.
The availability of cutting-edge technologies and expertise in the region contributes to its dominance. The U.S. trails behind with low prominence in this market. The downfall of Abbott’s Absorb BVS, coupled with a lack of other bioresorbable stents seeking FDA clearance to capitalize on the opportunity, has resulted in low immediate prospects for bioresorbable coronary stents in this region. On the upside, the clinical pipeline of second-generation bioresorbable stents with better device attributes and design features is expected to boost sales across the worldwide market, encompassing Europe, India, and North America.
Asia Pacific is expected to register the fastest CAGR of 16.8% through 2030. In addition to the growing coronary stenting procedure volumes on account of the high CVD-afflicted patient count, the region is witnessing a rapid adoption of CE and FDA-approved devices, which leads to strong regional sales revenue for bioresorbable coronary stents.
Moreover, the region has been investing extensively in improving its healthcare infrastructure, including developing modern hospitals, cardiac centers, and catheterization laboratories equipped with advanced medical technologies. These advancements enable healthcare providers to offer quality treatments, including the use of bioresorbable coronary stents, to patients. The availability of these facilities supports the growth of the market.
Key industry players are undertaking various strategies such as mergers & acquisitions, new product developments, collaborations & partnerships, and expansion strategies to improve their market penetration. For instance, in April 2022, Biosensors International Group, a manufacturer of interventional cardiology devices, received approval for BioFreedom, which is a drug-coated coronary stent system used to improve coronary luminal diameter in patients who are at a greater risk of bleeding. Following are some of the major participants in the global bioresorbable coronary stents market:
Boston Scientific Corporation
Meril Life Sciences Pvt. Ltd.
REVA Medical, LLC
Arterial Remodeling Technologies SA
Market size value in 2023
USD 163.5 million
Revenue forecast in 2030
USD 442.9 million
CAGR of 15.3% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
Boston Scientific Corporation; Medtronic; Cordis; Biotronik; Meril Life Sciences Pvt. Ltd.; Abbott; Elixir Medical; REVA Medical, LLC; Arterial Remodeling Technologies SA
Free report customization (equivalent to up to 8 analyst working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global bioresorbable coronary stents market report on the basis of brand and region:
Brand Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global bioresorbable coronary stents market size was estimated at USD 140.25 million in 2022 and is expected to reach USD 163.5 million in 2023.
b. The global bioresorbable coronary stents market is expected to grow at a compound annual growth rate of 15.3% from 2023 to 2030 to reach USD 442.9 million by 2030.
b. North America dominated the bioresorbable coronary stents market with a share of 37.4% in 2022. This is attributable to the clinical pipeline of second generation bioresorbable stents with better device attributes and design features.
b. Some of the players operating in bioresorbable coronary stents include BIOTRONIK, Meril Lifesciences Pvt. Ltd., Elixir Medical Corporation, REVA Medical, Arterial Remodeling Technologies, Amaranth Medical, Microport Scientific Corporation, and Arterius, competing against established drug-eluting coronary stent players.
b. Availability of post-approval, real-world evidence data for Magmaris, Magnitude and second generation Absorb is expected to be the turning point for the current lagging pace of this market.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."